ArticleThoracic cancer2021

ALK rearrangements as mechanisms of acquired resistance to osimertinib in EGFR mutant non-small cell lung cancer.

Helei Hou et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.